MitoImmune Therapeutics
Latest round
- Series B
Last raised
- Jul 2023
Total raised
- $39M
Investors
- 14
About MitoImmune Therapeutics
Established in 2018 and based in Seoul, South Korea, MitoImmune Therapeutics Inc. is a drug and biotechnology development company that uses mitochondria and proprietary technologies targeting mitochondria as a source for the development of new potential breakthrough therapies. The company’s lead program is based on the breakthrough scientific findings of its founder Soon Ha Kim at LG Life Sciences which was acquired by LG Chem in the end of 2017, and exclusively in-licensed the technology from LG Chem. The company mainly increases healthy lifespan by developing treatments for mitochondrial dysfunction-related necrosis and inflammatory diseases, and is conducting global and domestic Phase 2 clinical trials for Oral Mucositis of HNSCC patients and HSCT pre-conditioning regimen respectively, which has high unmet medical needs, and to carry out full-scale activities for global licensing deals.
Who invested in MitoImmune Therapeutics
14 investors across 3 rounds
See all investors in MitoImmune Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about MitoImmune Therapeutics
Who invested in MitoImmune Therapeutics?
MitoImmune Therapeutics has 14 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has MitoImmune Therapeutics raised?
MitoImmune Therapeutics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did MitoImmune Therapeutics last raise money?
MitoImmune Therapeutics's most recent round on record is a Series B, in Jul 2023.
What does MitoImmune Therapeutics do?
Established in 2018 and based in Seoul, South Korea, MitoImmune Therapeutics Inc.
Where is MitoImmune Therapeutics headquartered?
MitoImmune Therapeutics is headquartered in Seoul, South Korea.
Which VCs invest in companies like MitoImmune Therapeutics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at MitoImmune Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like MitoImmune Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.